Literature DB >> 15234857

Achieving the WHO/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost?

Juan Pablo Gutierrez1, Benjamin Johns, Taghreed Adam, Stefano M Bertozzi, Tessa Tan-Torres Edejer, Robert Greener, Catherine Hankins, David B Evans.   

Abstract

The "3 by 5" goal to have 3 million people in low and middle income countries on antiretroviral therapy (ART) by the end of 2005 is ambitious. Estimates of the necessary resources are needed to facilitate resource mobilisation and rapid channelling of funds to where they are required. We estimated the financial costs needed to implement treatment protocols, by use of country-specific estimates for 34 countries that account for 90% of the need for ART in resource-poor settings. We first estimated the number of people needing ART and supporting programmes for each country. We then estimated the cost per patient for each programme by country to derive total costs. We estimate that between US5.1 billion dollars and US5.9 billion dollars will be needed by the end of 2005 to provide ART, support programmes, and cover country-level administrative and logistic costs for 3 by 5.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234857     DOI: 10.1016/S0140-6736(04)16590-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

Review 1.  Methods to assess the costs and health effects of interventions for improving health in developing countries.

Authors:  David B Evans; Tessa Tan-Torres Edejer; Taghreed Adam; Stephen S Lim
Journal:  BMJ       Date:  2005-11-12

2.  The Economic Impact of AIDS Treatment: Labor Supply in Western Kenya.

Authors:  Harsha Thirumurthy; Joshua Graff Zivin; Markus Goldstein
Journal:  J Hum Resour       Date:  2008

3.  Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries.

Authors:  Daniel R Hogan; Rob Baltussen; Chika Hayashi; Jeremy A Lauer; Joshua A Salomon
Journal:  BMJ       Date:  2005-11-10

Review 4.  Harnessing the prevention benefits of antiretroviral therapy to address HIV and tuberculosis.

Authors:  Reuben Granich; Ying-Ru Lo; Amitabh B Suthar; Marco Vitoria; Rachel Baggaley; Carla Makhlouf Obermeyer; Craig McClure; Yves Souteyrand; Jos Perriens; James G Kahn; Rod Bennett; Caoimhe Smyth; Brian Williams; Julio Montaner; Gottfried Hirnschall
Journal:  Curr HIV Res       Date:  2011-09       Impact factor: 1.581

5.  HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions.

Authors:  Gesine Meyer-Rath; Mead Over
Journal:  PLoS Med       Date:  2012-07-10       Impact factor: 11.069

6.  Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence.

Authors:  Christine S M Currie; Katherine Floyd; Brian G Williams; Christopher Dye
Journal:  BMC Public Health       Date:  2005-12-12       Impact factor: 3.295

7.  The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis.

Authors:  Susan M Cleary; Di McIntyre; Andrew M Boulle
Journal:  Cost Eff Resour Alloc       Date:  2006-12-06

8.  Enhancing the comparability of costing methods: cross-country variability in the prices of non-traded inputs to health programmes.

Authors:  Benjamin Johns; Taghreed Adam; David B Evans
Journal:  Cost Eff Resour Alloc       Date:  2006-04-24

9.  A cost function for HIV prevention services: is there a 'u' - shape?

Authors:  Lorna Guinness; Lilani Kumaranayake; Kara Hanson
Journal:  Cost Eff Resour Alloc       Date:  2007-11-05

10.  Capacity utilization and the cost of primary care visits: implications for the costs of scaling up health interventions.

Authors:  Taghreed Adam; Steeve Ebener; Benjamin Johns; David B Evans
Journal:  Cost Eff Resour Alloc       Date:  2008-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.